FDA issues an emergency use authorization for a third COVID-19 vaccine, manufacturers ramp up production

-
BlogThe Food and Drug Administration on February 27 issued an emergency use authorization for Johnson & Johnson’s Janssen vaccine, the third vaccine for COVID-19 approved for adults and the first approved vaccine that rFDA issues an emergency use authorization for a third COVID-19 vaccine, manufacturers ramp up production
-
Blog
FDA issues an emergency use authorization for a third COVID-19 vaccine, manufacturers ramp up production
The Food and Drug Administration on February 27 issued an emergency use authorization for Johnson & Johnson’s Janssen vaccine, the third vaccine for COVID-19 approved for adults and the first approved vaccine that requires only one dose. The Pfizer and Moderna vaccines, which the FDA recommends recipients receive as a series of two doses about one month apart, received EUAs on December 11th and December 18th, respectively.
A clinical trial for the Janssen vaccine that was conducted in North America, South America and Africa found it was 66 percent effective and 72 percent effective in the United States. Additionally, the Janssen vaccine had about 85 percent efficacy against severe or critical COVID-19 cases.
Of benefit to county sites who are administering the vaccine, the Janssen vaccine can also be stored at warmer temperatures than the Pfizer and Moderna vaccines; which eases the logistical burden of storing the vaccine, and the need for specific storage supplies. The Janssen vaccine should be stored between 36°F to 46°F, whereas the Pfizer and Moderna vaccines should be stored between -112ºF to -76ºF and -13º to 5ºF, respectively. The Pfizer and Moderna vaccines could be stored at warmer temperatures for multiple weeks without expiring.
The news of a third effective vaccine comes as the federal government and its partners prepare to ramp up vaccine production and distribution. A subcommittee within the House Committee on Energy and Commerce held a hearing on February 22 where leadership from the 6 leading vaccine manufacturers testified about the rate of their companies’ vaccine production processes. The makers of the three approved vaccines made commitments to increase production:
- Pfizer is on track to have made 120 million doses available for shipment by the end of March, an addition 80 million doses by the end of May, and 100 million by July. It will increase weekly allotments from about 5 million at the end of February to about 13 million by the middle of March.
- Moderna is on track to have made 100 million doses available for shipment by the end of March, and hopes to have 200 total doses available by the end of May and 300 million total by July.
- Johnson & Johnson, which has begun shipping 4 million doses, pledged to have 20 million doses available by the end of March, 17 million doses below what it had agreed to produce by March 2021 in its contract with HHS. It has pledged to produced 100 million doses in the first half of 2021. On March 2, the Biden Administration announced a partnership between Johnson and Johnson and Merck to manufacture the Janssen vaccine.
During the hearing officials also discussed the possibility of producing booster shots to combat variants that the current vaccines do not protect against. For example, Novovax Executive Vice President John Trizzino described how its vaccine, which is in stage three of clinical trials, has shown promise in protecting against the South African variant. On Feb. 24, Moderna announced it had shipped a vaccine that targets the South African variant to the National Institute of Health for a clinical study.
While the approval of a third vaccine and the projected increase in manufacturing will equip counties with the supply needed to meet the growing vaccine demand in their communities, direct and flexible federal assistance and resources to counties - particularly direct dosage allocations - will give local governments more authority to provide resources and vaccine doses to the places and people that need them most. NACo encourages Senate lawmakers to swiftly pass the American Rescue Act, which will provide needed assistance to local entities working to vaccinate Americans across the country.
Additional Resources
- NACo’s COVID-19 Vaccine Distribution Toolkit
- NACo Blog: Biden administration unveils national vaccine strategy
- NACo Blog: FDA issues an emergency use authorization for the first COVID-19 vaccine, counties need funding as frontline distributors
The Food and Drug Administration on February 27 issued an emergency use authorization for Johnson & Johnson’s2021-03-05Blog2021-03-06
The Food and Drug Administration on February 27 issued an emergency use authorization for Johnson & Johnson’s Janssen vaccine, the third vaccine for COVID-19 approved for adults and the first approved vaccine that requires only one dose. The Pfizer and Moderna vaccines, which the FDA recommends recipients receive as a series of two doses about one month apart, received EUAs on December 11th and December 18th, respectively.
A clinical trial for the Janssen vaccine that was conducted in North America, South America and Africa found it was 66 percent effective and 72 percent effective in the United States. Additionally, the Janssen vaccine had about 85 percent efficacy against severe or critical COVID-19 cases.
Of benefit to county sites who are administering the vaccine, the Janssen vaccine can also be stored at warmer temperatures than the Pfizer and Moderna vaccines; which eases the logistical burden of storing the vaccine, and the need for specific storage supplies. The Janssen vaccine should be stored between 36°F to 46°F, whereas the Pfizer and Moderna vaccines should be stored between -112ºF to -76ºF and -13º to 5ºF, respectively. The Pfizer and Moderna vaccines could be stored at warmer temperatures for multiple weeks without expiring.
The news of a third effective vaccine comes as the federal government and its partners prepare to ramp up vaccine production and distribution. A subcommittee within the House Committee on Energy and Commerce held a hearing on February 22 where leadership from the 6 leading vaccine manufacturers testified about the rate of their companies’ vaccine production processes. The makers of the three approved vaccines made commitments to increase production:
- Pfizer is on track to have made 120 million doses available for shipment by the end of March, an addition 80 million doses by the end of May, and 100 million by July. It will increase weekly allotments from about 5 million at the end of February to about 13 million by the middle of March.
- Moderna is on track to have made 100 million doses available for shipment by the end of March, and hopes to have 200 total doses available by the end of May and 300 million total by July.
- Johnson & Johnson, which has begun shipping 4 million doses, pledged to have 20 million doses available by the end of March, 17 million doses below what it had agreed to produce by March 2021 in its contract with HHS. It has pledged to produced 100 million doses in the first half of 2021. On March 2, the Biden Administration announced a partnership between Johnson and Johnson and Merck to manufacture the Janssen vaccine.
During the hearing officials also discussed the possibility of producing booster shots to combat variants that the current vaccines do not protect against. For example, Novovax Executive Vice President John Trizzino described how its vaccine, which is in stage three of clinical trials, has shown promise in protecting against the South African variant. On Feb. 24, Moderna announced it had shipped a vaccine that targets the South African variant to the National Institute of Health for a clinical study.
While the approval of a third vaccine and the projected increase in manufacturing will equip counties with the supply needed to meet the growing vaccine demand in their communities, direct and flexible federal assistance and resources to counties - particularly direct dosage allocations - will give local governments more authority to provide resources and vaccine doses to the places and people that need them most. NACo encourages Senate lawmakers to swiftly pass the American Rescue Act, which will provide needed assistance to local entities working to vaccinate Americans across the country.
Additional Resources
- NACo’s COVID-19 Vaccine Distribution Toolkit
- NACo Blog: Biden administration unveils national vaccine strategy
- NACo Blog: FDA issues an emergency use authorization for the first COVID-19 vaccine, counties need funding as frontline distributors

About Blaire Bryant (Full Bio)
Legislative Director – Health | Large Urban County Caucus
More from Blaire Bryant
-
Blog
CDC announces $4 billion in funding for public health workforce, infrastructure and data systems
On June 23, the Centers for Disease Control and Prevention (CDC) announced Strengthening U.S. Public Health Infrastructure, Workforce, and Data Systems, a new, flexible funding opportunity that will provide nearly $4 billion over five years to improve critical public health infrastructure to health departments across the country. -
Webinar
Protecting Public Health: Vector Disease Management and Mosquito Emergency Response
Jun. 21, 2022 , 1:00 pm – 2:00 pmCounty leaders are working across different sectors to coordinate programs and services that impact the well-being of communities, especially when it comes to the strong connection between the environment and public health. -
Blog
CDC approves COVID-19 vaccine for children under 5
On June 18, the U.S. Centers for Disease Control and Prevention (CDC) approved the use of COVID-19 vaccines for children aged 6 months to 5 years old, following a recommendation from the Food and Drug Administration (FDA). -
Blog
Tell your county’s story by completing Medicaid and SNAP surveys
To better inform our understanding of the county role in administering Medicaid services and how counties can strengthen coordination between the Medicaid and the Supplemental Nutrition Assistance Program (SNAP), the National Association of Counties (NACo) invites county health and human services officials to complete two research surveys. -
Blog
Join NACo to tell your county’s story at the White House conference on hunger, nutrition and health
In advance of the September, 2022 White House Conference on Hunger, Nutrition and Health, the National Association of Counties (NACo) will host a County Listening Session on Thursday, June 30 at 3:00 p.m. EDT for county officials to share ideas and critical perspectives with White House officials and other federal partners. -
Blog
Healthy Counties Leadership Spotlight: Vice Chair Nick Macchione, Director, Health and Human Services Agency, San Diego County, Calif.
Hello Healthy Counties! I am Nick Macchione and currently serve as Vice-Chair of the Healthy Counties Advisory Board (HCAB). Since its inception as a NACO Presidential initiative by Commissioner Lenny Eliason I have proudly served in the various roles of member, vice-chair and chair of the HCAB.
-
Webinar
County Listening Session for the White House Conference on Hunger, Nutrition and Health
June 30, 2022 , 3:00 pm – 4:00 pmAs the front line of the social safety net, counties make significant investments in health and well-being to support our most vulnerable residents and are key partners with state and federal governments in efforts to combat hunger. In advance of the upcoming06303:00 pm<p>As the front line of the social safety net, counties make significant investments in health and well-being to support our most vulnerable residents and are key partners with state and federal governments in efforts to combat hunger.
-
Basic page
The Stepping Up Initiative
In May 2015, NACo and partners at the CSG Justice Center and APA Foundation launched Stepping Up: A National Initiative to Reduce the Number of People with Mental Illnesses in Jails.pagepagepage<h2>Overview</h2>
<blockquote>
<h3>Join the Initiative!</h3> -
Reports & Toolkits
COVID-19 Recovery Clearinghouse
The COVID-19 Recovery Clearinghouse features timely resources for counties, including allocation estimations, examples of county programs using federal coronavirus relief funds, the latest news and more.Reports & Toolkitsdocument03127:15 pmReports & Toolkits<table border="1" cellpadding="1" cellspacing="1" style="width:100%" summary="ad-block no-top-margin no-bullets">
<caption>Jump to Section</caption> -
Basic page
Live Healthy U.S. Counties
The National Association of Counties (NACo) Live Healthy Prescription, Health & Dental Discount Program is a NO-COST program available to all member counties.pagepagepage<h1>With <a id="naco" name="naco">NACo</a>, Saving Feels Better</h1>
Contact
-
Legislative Director – Health | Large Urban County Caucus(202) 942-4246
Related Posts
-
BlogCDC announces $4 billion in funding for public health workforce, infrastructure and data systemsJun. 28, 2022
-
BlogCDC approves COVID-19 vaccine for children under 5Jun. 21, 2022
-
BlogTell your county’s story by completing Medicaid and SNAP surveysJun. 21, 2022
Related Resources
-
Press ReleaseNational Association of Counties Partners with National Council for Mental Wellbeing to Deliver Mental Health First Aid Training to County WorkforceJun. 1, 2022
-
Reports & ToolkitsPromoting Health and Safety Through a Behavioral Health Continuum of CareMay. 24, 2022
-
Reports & ToolkitsToolkit for Counties: The 988 National Suicide Prevention LifelineMay. 23, 2022
Related Events
-
30Jun2022Webinar
County Listening Session for the White House Conference on Hunger, Nutrition and Health
Jun. 30, 2022 , 3:00 pm – 4:00 pm
More From
-
Data sharing can keep ‘familiar faces’ from facing jail’s revolving door
In many communities, vital service systems do not have the means to communicate and share information about their most frequent users, possibly letting their underlying needs go unmet.
Learn More